Skip to content

Envista Holdings

US · NVST #2329 by market cap Listed 2019
22.91 -0.36 -1.55%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 1.27 In line with history 54th percentile
5-year average 1.26 · #9 of 51 in Medical Instruments & Supplies
P/E ratio 6.36 Cheap vs history 30th percentile
5-year average 33.18 · forward 17.74 · #3 of 27 in Medical Instruments & Supplies
P/S ratio 1.36 Cheap vs history 31st percentile
5-year average 1.77 · forward 1.34 · #10 of 51 in Medical Instruments & Supplies

Vs. peers Medical Instruments & Supplies

Company Market cap P/E (TTM) P/B Div yield
Envista Holdings (NVST) 3.67B 5.95 1.19 0.00%
Intuitive Surgical (ISRG) 138.33B 48.25 8.65 0.00%
Becton Dickinson & Co (BDX) 57.96B 52.02 2.35 1.97%
Alcon (ALC) 35.92B 54.24 1.64 0.48%
ResMed (RMD) 33.14B 21.46 5.57 1.04%
Medline (MDLN) 32.55B 57.52 2.76 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★★ Fair value29.07 Economic moatNone UncertaintyLow

Trading 26.9% below Morningstar's fair value estimate.

Fair value

Envista Holdings Corp earns a 5-star quantitative star rating, reflecting our opinion that this share class offers a compelling opportunity for investors. The stock currently trades at a 16% discount to our quantitative fair value estimate of $29.07 per share, which is reinforced by this estimate's low uncertainty rating.

The company's valuation metrics strengthen our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 76.4%, which lies in the top 45% compared with global peers. The market price is low relative to the book (accounting) value of the company's equity, which contributes to our view that shares are undervalued.

The company's profitability is an additional encouraging factor. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. The firm's earnings yield of 16.6%, a core component of profitability, falls in the top 10% globally. This suggests that it is generating substantial earnings relative to its share price, which further promotes our favorable price/fair value ratio.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:33 · For reference only, not investment advice and not tailored to your situation.

Envista Holdings discussion 0 comments

Add a comment